What is  Non Invasive Neuromodulation?

ENSr’s FIRSTtx Non Invasive Neuromodulation technology uses an advanced form of electrotherapy that is safe and effective in treating acute, chronic and post-operative pain. Non invasive neuromodulation functions on two physiological principles: that the body has its own healing capabilities and that we can promote this ability to recover or heal by stimulation of the areas of the brain responsible for regulation of the autonomic nervous system and achieving homeostasis. Non invasive neuromodulation technology is a therapeutic electrotherapy delivered via the skin, is hypothesized to produce both local effects – by stimulating the skin, muscle and blood vessels – as well as a general influence – by an effect on nervous and endocrine systems. It is further hypothesized that the pattern of electrical impulses stimulates nervous pathways via active points in the skin in an effort to restore and to improve the regulation of the disease and pain affected organs and tissues.

Non invasive neuromodulation technology relies on the body’s mechanism of adaptation ensuring dynamic equilibrium and homeostasis. Regulation of the body’s vital functions is achieved through close connection and interaction of the nervous and endocrine systems.

The effects of these systems result in the release of biologically active chemical modulators, called neuromediators. Examples of these neuromediators are:

amine: acetylcholine, noradrenalin, adrenalin, dopamine, serotonin epinephrine, norepinephrine, histamine
amino acids: glycine, glutamic, aspartic and gammaaminobutyric acid.
purine nucleotides: adenosine, cytidine, guanosine, thymidine
neuropeptides: enkephallin, neuropeptide Y, cholecystokinin, substance P, neurotensin.

The largest group of chemical modulators are the neuromediators and include endorphins (the ‘feel good’ chemical modulator), enkephalins and bradykinin.

The most important chemical modulators are neuropeptides. These are the main modulator of neural activity of the thin non-myelinated, ‘difficult-to-excite’ C-fibers. These neuropeptide-producing nerve fibers make up more than 70% of the body’s neural tracts. C-fibers specific properties enable the production of a powerful analgesic effect, which is brought about by the release of neuropeptides, once the C-fiber is activated.

The main goal of Non Invasive Neuromodulation therapy is that a maximum number of C-fibers are activated to induce the secretion of a sufficient amount of neuropeptides. This is achieved by active feedback, bipolar electric impulse and individually dosed influence.


The characteristics of the impulse are such that the probability of excitation of the thin neuropeptide-secreting C-fibers is higher than conventional methods of electrotherapy ₉ ₁₀ ₁₁.

The device enables a maximal part of the nervous tissue to be activated. This is necessary for the achievement of an optimal response from the patient’s body.

The electrical signals generated by the FIRSTtx device are similar in form to the body’s own natural neurological impulses. This way the body recognizes them as compatible and non invasive. By placing the device on the skin, the FIRSTtx facilitates pain relief while triggering and enhancing the recovery process.


The device can be used regardless of the type of pain diagnosis and is therefore a non-specific approach. However depending on the complaint or ailment of the individual.

Clinical experience with NINM devices has indicated that the optimal therapeutic effect is achieved when there is a maximal variability of the impulse during treatment ₁₂ ₁₃ ₁₄.

The optimum therapeutic results are always dependent upon the individual’s body’s response and therefore individual to each user. As the device monitors and evaluates treatment results it independently delivers the correct impulse without the possibility of overdosing and hence few side effects.

9. Somers D, Clemente F R, TENS for the management of neuropathic pain: The effects of frequency and electrode position on prevention of allodynia in a rat model of CRPS type II, Phys Ther, Vol. 86, no.5, 2006: pg 698-709
10. Han J S, Acupuncture: neuropeptide release produced by electrical stimulation of different frequencies. Trends in Neurosciences, Vol. 26, No.1, January 2003
11. Hamza, M.A. et al. (1999) Effect of the frequency of transcutaneous electrical nerve stimulation on the postoperative opioid analgesic requirement and recovery profile. Anesthesiology 91, 1232–1238
12. Melzack R: Prolonged relief of pain by brief, intense transcutaneous somatic stimulation. Pain. 1975;1: 357-373.
13. Chandran P, Sluka KA. Development of opioid tolerance with repeated transcutaneous electrical nerve stimulation administration. Pain. 2003;102:195–201
14. Josimari M. DeSantana, PhD, Valter J. Santana-Filho, MSc, Kathleen A. Sluka, PhD: Modulation Between High- and Low-Frequency Transcutaneous Electric Nerve Stimulation Delays the Development of Analgesic Tolerance in Arthritic Rats Arch Phys Med Rehabil Vol 89, April 2008: pg 754-760